Dividend per share
Fiscal year ending March 2026Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.
Under the medium-term management plan, STS2030 Revision, the Company has set a dividend on equity (DOE) of at least 4% as a shareholder return indicator and aims to steadily and consistently increase dividends in line with growth in corporate value.
| Item | Details |
|---|---|
| Dividend per share | 33 yen → 38 yen（+15.2%） |
| Total Annual Dividends | 66 yen → 71 yen（+7.6%） |
| Previous-period results (per share) | Interim 28 yen / End of period 33 yen / Annual 61 yen |
| Dividend policy | Under the medium-term management plan, STS2030 Revision, the Company has set a dividend on equity (DOE) of at least 4% as a shareholder return indicator and aims to steadily and consistently increase dividends in line with growth in corporate value. |
| Whether Submission to the General Meeting of Shareholders Is Required | Board of directors resolution only |
| Fiscal Period Covered | Fiscal year ending March 2026 |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decision was based on a comprehensive consideration of progress in the HIV business, growth in domestic and overseas operations, the Company's financial position, and shareholder return indicators such as EPS, DOE and ROE under the medium-term management plan. The Company has set a DOE of at least 4% as a shareholder return indicator and has also stated its policy of steadily increasing dividends in line with growth in corporate value.